Integrated using UMI-77 and Curcumin Synergistic Treating Osteosarcoma by Targeting a Cuproptosis-Related Prognostic Model

Abstract

Abstract Background Among malignant bone sarcomas, osteosarcoma (OS) is the most frequent among young people. In recent studies, cuproptosis has been shown to play an important role in tumor progression. Evidence demonstrates that the combinatorial treatment with traditional Chinese medicine and western medicine improves the therapeutic effect on cancer, including OS. However, the combinatorial treatment targeting cuproptosis for OS remains elusive. Materials and Methods LASSO regression analysis was employed to establish and evaluate a cuproptosis-related prognostic model. The CIBERSORT algorithm was performed to demonstrate the significant differences in immune cell infiltration between low- and high-risk groups. Next, the CellMiner database was used to obtain potential drugs which target the risk score-related genes. Finally, we performed the network pharmacology and molecular docking studies to explore the combination of Chinese and western medicine on treatment of osteosarcoma. Results We found that the Chinese medicine, curcumin, and the western medicine, UMI-77 synergistic treating OS both in vivo and vitro. LASSO regression analysis was employed to establish and evaluate a cuproptosis-related prognostic model. Moreover, the CIBERSORT algorithm was performed to demonstrate the significant differences in immune cell infiltration between low- and high-risk groups. Notably, prognostic genes were related to 106 drugs obtained from the CellMiner database. Network pharmacology and molecular docking studies demonstrated that curcumin, the main active ingredient of curcumaelongae Rhizoma, targeted the suppressor gene, CLTC. Conclusion Our findings demonstrated that the combination of curcumin and UMI possess certain effect on osteosarcoma. And this study provides a theoretical framework for the integration of traditional Chinese medicine with western medicine for treating OS.